摘要
肝癌（HCC）是全球最富有挑战性的恶性肿瘤之一。HCC需要综合治疗，目前尚无特效的治疗药物。分子靶向药物的发展，使HCC的全身治疗有了新的希望。阐述了分子靶向药物的现状，多激酶抑制剂、抗血管生成和抗表皮生长因子受体药物在临床上的进展，认为索拉芬尼是晚期HCC的新的标准治疗药物。
It is well appreciated that hepatocellular carcinoma （HCC） represents one of the most challenging malignancies of worldwide importance. HCC is a disease that requires multidiseiplinary management. There has been no widely accepted standard for systemic therapy for this disease until recently. However, with the arrival of newly developed, molecularly targeted agents, there has been renewed interest in developing novel systemic therapy in HCC. For this review, the authors eoncisely summarized the current status of molecular targeted agents： multikinase inhibitor, antiangiogenesis and anti-EGFR agents, which are under clinical development, focus on new agents with promise, particularly sorafenib, a drug that appear to be the new standard of care for advanced HCC.
出处
《肿瘤研究与临床》
CAS
2008年第11期721-723,共3页
Cancer Research and Clinic
关键词
肝肿瘤
药物疗法
靶向治疗
Liver neoplasms
Drug therapy
Targeted therapy
